The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention

被引：17

作者：

Allegra, Alessandro ^{[1
]}

Innao, Vanessa ^{[1
]}

Gerace, Demetrio ^{[1
]}

Allegra, Andrea Gaetano ^{[1
]}

Vaddinelli, Doriana ^{[1
]}

Bianco, Oriana ^{[1
]}

Musolino, Caterina ^{[1
]}

机构：

[1] Univ Messina, Div Hematol, Dept Dept Human Pathol Adulthood & Childhood Gaet, Via Consolare Valeria, I-90100 Messina, Italy

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2018年 / 53卷

关键词：

Adipose tissue; Multiple myeloma; Adipocytes; Adipokine; Myelomagenesis; BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; BONE-MARROW ANGIOGENESIS; NON-HODGKIN-LYMPHOMA; CELL-GROWTH; FACTOR-I; HEMATOLOGIC MALIGNANCIES; CIRCULATING ADIPONECTIN; MONOCLONAL-ANTIBODY; PANCREATIC-CANCER;

D O I：

10.1016/j.ejim.2018.05.033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In addition to its capacity to store lipids the adipose tissue is now identified as a real organ with both endocrine and metabolic roles. Preclinical results indicate that modifying adipose tissue and bone marrow adipose tissue (BMAT) could be a successful multiple myeloma (MM) therapy. BMAT interrelates with bone marrow cells and other immune cells, and may influence MM disease progression. The BM adipocytes may have a role in MM progression, bone homing, chemoresistance, and relapse, due to local endocrine, paracrine, or metabolic factors. BM adipocytes isolated from MM subjects have been shown to increase myeloma growth in vitro and may preserve cells from chemotherapy-induced apoptosis. By producing free fatty acids and emitting signaling molecules such as growth factors and adipokines, BM adipocytes are both an energy font and an endocrine signaling factory. This review should suggest future research approaches toward developing novel treatments to target MM by targeting BMAT and its products.

引用

页码：12 / 20

页数：9

共 145 条

[41]

FAVREAU F, 2017, LEUKEMIA

[42] Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway [J].